Clinical trials: Monoclonal
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
HCC
PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT
It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.
- Trial name
- NCT04165174
- Testing
- Terepril monoclonal antibody; Apatinib, SBRT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Advanced Solid Tumors
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.
- Trial name
- RELATIVITY-111 (NCT05498480)
- Testing
- Relatlimab, Nivolumab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery.
- Trial name
- ROXI-VTE II (NCT06454630)
- Testing
- REGN7508, Enoxaparin
- Where
- 14 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 179 people
- Sponsor
- Regeneron Pharmaceuticals
Systemic Lupus Erythematosus
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE…
- Trial name
- NCT00724867
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Where
- 51 sites in United States
- Volunteers
- 268 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05186909
- Testing
- CM310
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Keymed Biosciences Co.Ltd
Neuralgia, Postherpetic
RN624 For Pain Of Post-Herpetic Neuralgia
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
- Trial name
- NCT00568321
- Testing
- RN624
- Where
- 31 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers…
- Trial name
- NCT02908906
- Testing
- JNJ-63723283
- Where
- 20 sites in United States, Moldova and 5 more
- Volunteers
- 234 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment
- Trial name
- NCT00661284
- Where
- 5 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Chugai Pharmaceutical
Colorectal Cancer
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
- Trial name
- GEN206 (NCT00677924)
- Testing
- Zalutumumab
- Where
- 3 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Genmab
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Advanced Solid Tumor
Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors
In this study, patients of advanced gastric adenocarcinoma with failed first-line chemotherapy-line or advanced mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced solid carcinoma will be…
- Trial name
- NCT03704246
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- 30 sites in China
- Volunteers
- 123 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Non-Small Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then…
- Trial name
- NCT00918203
- Testing
- Olaratumab, Paclitaxel, Carboplatin
- Where
- 23 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003741
- Testing
- monoclonal antibody HeFi-1
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Non-Small Cell Lung Cancer, Colorectal Cancer
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT07216105
- Testing
- FT836, Cetuximab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- Fate Therapeutics
Loiasis
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood.
- Trial name
- NCT01111305
- Testing
- Reslizumab, Diethylcarbamazine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
This study will examine the safety of Zenapax (daclizumab) in patients with multiple sclerosis (MS). MS is thought to be caused by an over-reactive immune response.
- Trial name
- NCT00071838
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV
A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
Background: HIV causes AIDS, a serious disease that can lead to fatal infections. HIV infection can be controlled but not cured, nor is there a vaccine to prevent it.
- Trial name
- NCT05627258
- Testing
- VRC-HIVMAB0115-00-AB
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.